Clinical trials
Combination Therapy clinical trials
Below are recruiting combination therapy clinical trials, each written for real people, not researchers. We’re tracking 888 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT07601737RecruitingPhase 2
Nimotuzumab with immunotherapy and chemotherapy for head and neck cancer
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
ShanghaiAges 18–75 - NCT07222735RecruitingPhase 1
CAR T cells and radiation for children with sarcoma
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
Memphis, TennesseeAges Up to 21 years - NCT07334431RecruitingPhase 1/Phase 2
A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Zhengzhou, HenanAges 18–75 - NCT07564453RecruitingPhase 2
Immunotherapy plus chemotherapy for newly diagnosed B-cell leukemia
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Suzhou, JiangsuAges 15–65 - NCT06069830Recruiting
PET scan and EBV test guided treatment for nasal NK/T cell lymphoma
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07327710Enrolling by invitation
Brain-Computer Interface and Electrical Stimulation for Facial Paralysis
This trial tests a non-invasive treatment that combines a brain-computer interface with mild electrical stimulation to help people with one-sided facial paralysis regain movement. It aims to improve facial muscle function by retraining the brain and muscles together.
Changzhou, JiangsuAges 18–75 - NCT05837455RecruitingPhase 2
Biomarker-guided treatment for early breast cancer before surgery
This trial looks at whether using tumor test results (biomarkers) can help guide the best hormone treatment and chemotherapy before surgery. It focuses on people with stage II or III, ER-positive, HER2-negative breast cancer, with the goal of improving how well the tumor responds before it is removed.
St Louis, MissouriAges 18 years+ - NCT06772454Recruiting
Testing a new drug combo for advanced lung cancer with COPD
This trial tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and inhaled steroids helps people with advanced lung cancer who also have COPD. The goal is to see if this combination improves outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT05039632RecruitingPhase 1/Phase 2
NBTXR3 plus radiation with anti-PD-1 for advanced lung or liver cancers
This study tests whether adding NBTXR3 (given into a tumor) and targeted radiation to anti–PD-1/PD-L1 immunotherapy can improve cancer control in advanced cancers that have spread to the lung and/or liver. Participants may be assigned to different radiation approaches to try to trigger tumor shrinkage in both treated and nearby or distant tumor areas.
Houston, TexasAges 18 years+ - NCT06177925RecruitingPhase 2
Immunotherapy plus chemoradiation for limited spread SCLC
This trial tests a combination of an immunotherapy drug (adebrelimab) plus standard chemotherapy and radiation for people with extensive-stage small cell lung cancer that has only spread to a few places. The goal is to see if this approach can help control the cancer better.
GuangzhouAges 18–75 - NCT06794073Recruiting
Combination therapy for advanced liver cancer
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06719700RecruitingPhase 2
Chemo-radiation with two drugs for limited-stage small cell lung cancer
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07025226RecruitingEarly Phase 1
Combination drugs and vaccine for glioma with remaining tumor
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
Rochester, MinnesotaAges 18 years+ - NCT06814496RecruitingPhase 1/Phase 2
Radiation and immunotherapy combo for DLL3-positive cancers
This trial combines radiation with an immunotherapy drug called tarlatamab to treat cancers that make a protein called DLL3. The goal is to see if this combination works better than either treatment alone for people with certain types of lung cancer and other tumors that have not responded to prior therapy.
Tucson, ArizonaAges 18–99 - NCT04754321RecruitingPhase 1
Test immunotherapy with salvage surgery and IORT for head and neck cancer
This Phase 1 trial tests a new plan that combines immunotherapy with surgery, plus a targeted radiation treatment called IORT. It is for people whose head and neck squamous cell cancer has come back or never fully went away and can be operated on. The goal is to shrink or control the cancer and see how safe the approach is.
Columbus, OhioAges 18 years+ - NCT06501625RecruitingPhase 1/Phase 2
Targeted therapy plus immunotherapy for IDH1-mutated bile duct cancer
This trial tests a new combination of three drugs (ivosidenib, durvalumab, and gemcitabine/cisplatin) as a first treatment for people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Alamitos, CaliforniaAges 18 years+ - NCT04322318RecruitingPhase 2
Study of combination chemotherapy for Wilms tumor in children
This Phase 2 trial tests combination chemotherapy for children with certain types of Wilms tumor—either newly diagnosed diffuse anaplastic Wilms tumor or favorable Wilms tumor that has come back. The goal is to see how well the treatment controls the tumor and is tolerable for children.
Birmingham, AlabamaAges Up to 30 years - NCT07236216Recruiting
Brain stimulation with walking training for stroke recovery
This study tests if combining brain stimulation (tES) with a walking training program can improve thinking, movement, and brain activity in stroke survivors. You may benefit if you have some walking ability and no major health risks.
Nakhon PathomAges 18–80 - NCT06064097RecruitingPhase 2
Nivolumab plus chemo for young people with nasopharyngeal cancer
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
Birmingham, AlabamaAges Up to 21 years - NCT06124157RecruitingPhase 2
Targeted therapy plus chemo for children with Ph+ or Ph-like B-ALL
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Birmingham, AlabamaAges 1 year–46 years - NCT05136846RecruitingPhase 1
Papaverine with chemoradiation for stage II–III lung cancer
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT06324240RecruitingPhase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Atlanta, GeorgiaAges 18 years+
Hear when a new Combination Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for combination therapy?
- Yes. Clin2 currently lists 888 recruiting combination therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a combination therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a combination therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.